Drug
BXCL501
BXCL501 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_3
3
60%
Phase Distribution
0
Early Stage
2
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
40.0%
2 of 5 finished
Non-Completion Rate
60.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(3)
Detailed Status
Completed2
Terminated2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (40.0%)
Phase 33 (60.0%)
Trials by Status
completed240%
terminated240%
withdrawn120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
NCT05271552
completedphase_3
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCT05658510
terminatedphase_3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
NCT05665088
terminatedphase_2
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
NCT05276830
withdrawnphase_2
Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
NCT05313386
Clinical Trials (5)
Showing 5 of 5 trials
NCT05271552Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
NCT05658510Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
NCT05665088Phase 3
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
NCT05276830Phase 2
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
NCT05313386Phase 2
Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5